Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Short-term Investments (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Short-term Investments for 15 consecutive years, with $767.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 8.98% year-over-year to $767.4 million, compared with a TTM value of $767.4 million through Dec 2025, down 8.98%, and an annual FY2025 reading of $767.4 million, down 8.98% over the prior year.
  • Short-term Investments was $767.4 million for Q4 2025 at Neurocrine Biosciences, down from $774.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $899.2 million in Q2 2024 and bottomed at $454.8 million in Q3 2021.
  • Average Short-term Investments over 4 years is $741.4 million, with a median of $780.5 million recorded in 2023.
  • The sharpest move saw Short-term Investments increased 10.13% in 2024, then dropped 20.86% in 2025.
  • Year by year, Short-term Investments stood at $454.8 million in 2021, then soared by 71.61% to $780.5 million in 2023, then rose by 8.02% to $843.1 million in 2024, then fell by 8.98% to $767.4 million in 2025.
  • Business Quant data shows Short-term Investments for NBIX at $767.4 million in Q4 2025, $774.6 million in Q3 2025, and $711.6 million in Q2 2025.